<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="27855">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02744092</url>
  </required_header>
  <id_info>
    <org_study_id>AFT-28</org_study_id>
    <secondary_id>CER-1503-29805</secondary_id>
    <nct_id>NCT02744092</nct_id>
  </id_info>
  <brief_title>Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer</brief_title>
  <acronym>CANVAS</acronym>
  <official_title>Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance Foundation Trials, LLC.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Patient-Centered Outcomes Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance Foundation Trials, LLC.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin
      vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The intervention
      strategy is Direct Oral AntiCoagulants (DOAC) therapy with edoxaban, apixaban, rivaroxaban,
      or dabigatran. The comparator is low molecular weight heparin (LMWH) alone or with warfarin.
      The information gained will empower cancer patients and physicians to make more informed
      choices about anticoagulation strategies to manage VTE.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Venous blood clots affect nearly a million Americans each year. Venous clots in the legs are
      called deep venous thrombosis (DVT) and are dangerous because they travel to the lungs where
      they cause blockages known as pulmonary emboli (PE). DVT and PE are called venous
      thromboemboli (VTE). Cancer is a risk factor with nearly 200,000 VTEs in cancer patients
      each year. The purpose of VTE treatment is to prevent the initial clot from spreading and to
      prevent new clots from forming. This is accomplished by thinning the blood, or
      anticoagulation. Without anticoagulation, VTEs recur and are often fatal.

      Recently, the FDA has approved 4 new Direct Oral AntiCoagulants (DOACs) for preventing VTE
      recurrence. Few cancer patients were included in the efficacy trials, and practice
      guidelines fall silent on whether switching to DOAC therapy is advisable. To fill this
      knowledge gap, the Alliance Foundation Trials LLC, a research network of academic and
      community practices across the US, is conducting a pragmatic randomized effectiveness trial.

      The overarching objective of the study is to determine the effectiveness of LMWH/ warfarin
      vs. DOAC anticoagulation for preventing recurrent VTE in cancer patients. The investigators
      will conduct a trial of 940 cancer patients followed for 6 months. The intervention strategy
      is DOAC therapy with edoxaban, apixaban, rivaroxaban, or dabigatran. The comparator is LMWH
      alone or with warfarin. Within each arm, patients can choose the agent they prefer based on
      side effects, drug interactions, and practical issues such as co-pays. The trial compares
      these two strategies in terms of treatment: 1) benefits based on VTE recurrence; 2) harms
      based on bleeding rates; 3) burdens based on patients' reports of their experiences; and 4)
      mortality rates.

      The investigators hypothesize that the benefits, harms and burdens of DOAC treatment will be
      non-inferior to, or better than, usual care with LMWH/ warfarin among cancer patients. The
      information gained will empower cancer patients and physicians to make more informed choices
      about anticoagulation strategies to manage VTE.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative VTE recurrence reported by participants (via study-specific questionnaire) or clinicians (via study-specific case report form)</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the effectiveness of anticoagulation with a DOAC (intervention) with LMWH/warfarin (comparator) for preventing VTE recurrence in patients with cancer based on cumulative VTE recurrence reported by patients or clinicians at 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative rates of major bleeding reported by participants (via study-specific questionnaire) or clinicians (via study-specific case report form)</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the harms of DOAC vs. LMWH/warfarin therapy for cancer patients with VTE based on the cumulative rate of major bleeding at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life reported by participants via the Optum SF-12v2 Health Survey questionnaire</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>To compare the impact of DOAC vs. LMWH/warfarin therapy on the health related quality of life (HRQOL) for cancer patients with VTE at 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of anticoagulation therapy reported by participants via the Anti-Clot Treatment Scale (ACTS) questionnaire</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>To compare the burden of anticoagulation therapy with DOAC vs. with LMWH/warfarin for cancer patients with VTE at 3 and 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality reported by participants' surrogates (via study-specific questionnaire) or clinicians (via study-specific case report form)</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the impact of DOAC vs. LMWH/warfarin therapy on mortality in cancer patients with VTE based on survival at 6 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Nothing to report</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">940</enrollment>
  <condition>Cancer</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Vein Thrombosis (DVT)</condition>
  <condition>Pulmonary Embolism (PE)</condition>
  <condition>Blood Clot</condition>
  <arm_group>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC). There are four FDA-approved DOAC drugs that may be used for this study: Rivaroxaban, Apixaban, Edoxaban, or Dabigatran. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin. There are three FDA-approved LMWH drugs that may be used for this study: Dalteparin, Enoxaparin, or Fondaparinux. The treatment (including dosage form, dosage, frequency and duration) should be administered in accordance with the drug's FDA package insert, and all modifications are at the discretion of the treating investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Preference Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If an eligible participant is offered randomization and declines randomization, then a limited number of participants (up to N=190) will be allowed to enroll in the Preference Cohort. In this case, the treating physician and patient choose Arm 1 or Arm 2 (non-randomized).
Preference cohort: Non-randomized Arm 1 will get anticoagulation therapy with a Direct Oral AntiCoagulant (DOAC).
Preference cohort: Non-randomized Arm 2 will get anticoagulation therapy with low molecular weight heparin (LMWH) with or without a transition to warfarin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Savaysa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 1</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Coumadin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalteparin</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Fragmin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>Anticoagulation therapy.</description>
    <arm_group_label>Randomized Arm 2</arm_group_label>
    <arm_group_label>Preference Cohort</arm_group_label>
    <other_name>Arixtra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced solid tumor cancer, lymphoma, or myeloma (no time restrictions
             or limitations) -OR- diagnosis of early stage solid tumor cancer, lymphoma, or
             myeloma &lt;= 12 months prior to study enrollment

          -  Diagnosis of VTE &lt;= 30 days prior to study enrollment for which potential benefits of
             anticoagulation therapy to prevent recurrence of VTE are felt by the treating
             physician to exceed the potential harms

               -  Any anticoagulation drug/strategy may be used to treat the index VTE; protocol
                  treatment will begin &lt;= 30days after the index VTE diagnosis date

          -  Treating physician intends to put participant on anticoagulation therapy for at least
             three months.

          -  Age &gt;= 21 years

          -  Platelet count is &gt;= 50,000/mm^3 (&lt;= 7 days prior to enrollment)

          -  CrCl (Creatinine Clearance) is &gt;= 15 ml/min (&lt;= 7 days prior to enrollment)

        Exclusion Criteria:

          -  Diagnosis of acute leukemia

          -  Has ever received or is scheduled to receive an Allogeneic Hematopoietic Stem Cell
             Transplantation (alloHSCT)

               -  Patients who have ever received an Autologous Hematopoietic Stem Cell
                  Transplantation (autoHSCT) ARE eligible.

               -  Patients who are scheduled to receive an Autologous Hematopoietic Stem Cell
                  Transplantation (autoHSCT) are NOT eligible

          -  Ongoing, clinically significant bleeding (CTCAE grade 3 or 4)

          -  Ongoing therapy with a P-gp inhibitor (e.g., nelfinavir, indinavir, or
             saquinavir-protease inhibitors for HIV) as these drugs interact with the factor Xa
             inhibitors

          -  Therapy with any azole antifungals (e.g., itraconazole, ketaconazole, voriconazole)
             at the time of enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Schrag, MD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Alliance Foundation Trials, LLC.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Connors, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Alliance Foundation Trials, LLC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deborah Schrag, MD MPH</last_name>
    <phone>617-582-8301</phone>
    <email>deb_schrag@dfci.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Connors, MD</last_name>
    <phone>617-525-9337</phone>
    <email>jconnors@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Middlesex Hospital</name>
      <address>
        <city>Middletown</city>
        <state>Connecticut</state>
        <zip>06457</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suasnna Hong, MD</last_name>
      <phone>860-358-2070</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Stamford Hospital</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K.M. Steve Lo, MD</last_name>
      <phone>203-276-8450</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ben Yan, MD</last_name>
      <phone>727-461-8526</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Breast Cancer Center at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Abraham, MD</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Abraham, MD</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Regional Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Abraham, MD</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hollis Cancer Center</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madhavi Venigalla, MD</last_name>
      <phone>863-904-1900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Breast Cancer Center at Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Abraham, MD</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute at Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Abraham, MD</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital West</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Abraham, MD</last_name>
      <phone>954-265-4325</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carle on Vermillion</name>
      <address>
        <city>Danville</city>
        <state>Illinois</state>
        <zip>61938</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhao, MD</last_name>
      <phone>217-431-7657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carle - Effingham</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhao, MD</last_name>
      <phone>217-347-6400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carle - Mattoon/Charleston</name>
      <address>
        <city>Mattoon</city>
        <state>Illinois</state>
        <zip>61938</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhao, MD</last_name>
      <phone>217-258-3657</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Carle Foundation Hospital/Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujie Zhao, MD</last_name>
      <phone>217-383-3010</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reid Health</name>
      <address>
        <city>Richmond</city>
        <state>Indiana</state>
        <zip>47374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Riggs, MD</last_name>
      <phone>765-983-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Martin, MD</last_name>
      <phone>502-562-4369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norton Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Martin, MD</last_name>
      <phone>502-629-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Martin, MD</last_name>
      <phone>502-562-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville Physicians, PSC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Martin, MD</last_name>
      <phone>502-583-8303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Louisville, Division of Surgical Oncology</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Martin, MD</last_name>
      <phone>502-629-3355</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>DF/BWCC at Milford Regional Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>01757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Constantine, MD</last_name>
      <phone>617-632-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Rosovsky, MD</last_name>
      <phone>617-632-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Connors, MD</last_name>
      <phone>617-632-3784</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Schrag, MD</last_name>
      <phone>617-582-8301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lowell General Hospital</name>
      <address>
        <city>Lowell</city>
        <state>Massachusetts</state>
        <zip>01854</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Zuniga, MD</last_name>
      <phone>978-937-6800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>South Shore Hospital</name>
      <address>
        <city>South Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meredith Faggen, MD</last_name>
      <phone>781-624-8000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Ltd./St. Francis Hospital</name>
      <address>
        <city>Escanaba</city>
        <state>Michigan</state>
        <zip>49829</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veterans Administration/Harry S Truman Memorial Hospital</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clint Kingsley, MD</last_name>
      <phone>573-814-6000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center University of Missouri Healthcare</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clint Kingsley, MD</last_name>
      <phone>573-882-7440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/New Hampshire Oncology Hematology</name>
      <address>
        <city>Londonderry</city>
        <state>New Hampshire</state>
        <zip>03053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fred Briccetti, MD</last_name>
      <phone>603-552-9100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Naqvi, MD</last_name>
      <phone>315-464-4353</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Clinton</city>
        <state>North Carolina</state>
        <zip>28328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Atkins, MD</last_name>
      <phone>910-592-5727</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Atkins, MD</last_name>
      <phone>919-580-0000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Jacksonville</city>
        <state>North Carolina</state>
        <zip>28546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Atkins, MD</last_name>
      <phone>910-353-0824</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kenansville Medical Center</name>
      <address>
        <city>Kenansville</city>
        <state>North Carolina</state>
        <zip>28349</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Watson, MD</last_name>
      <phone>910-275-1814</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kinston Medical Specialists, P.A.</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Watson, MD</last_name>
      <phone>252-559-2201</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lenoir Memorial Hospital</name>
      <address>
        <city>Kinston</city>
        <state>North Carolina</state>
        <zip>28501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Watson, MD</last_name>
      <phone>252-522-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onslow Medical Center</name>
      <address>
        <city>Richlands</city>
        <state>North Carolina</state>
        <zip>28574</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Watson, MD</last_name>
      <phone>910-324-7328</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians LLC, Miami Valley South</name>
      <address>
        <city>Centerville</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-293-1622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tzu-Fei Wang, MD</last_name>
      <phone>614-293-9441</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians LLC, Samaritan North</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-293-1622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Clincial Oncology Program</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-775-1350</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians LLC, Atrium</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-245-6308</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians, Wayne</name>
      <address>
        <city>Greenville</city>
        <state>Ohio</state>
        <zip>45331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-293-1622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greater Dayton Cancer Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45409</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-293-1622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kettering Medical Center</name>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <zip>45429</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-298-3399</phone>
      <phone_ext>57556</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center - Maumee</name>
      <address>
        <city>Maumee</city>
        <state>Ohio</state>
        <zip>43537</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rex Mowat, MD</last_name>
      <phone>419-479-5605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic Cancer Center - Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rex Mowat, MD</last_name>
      <phone>419-479-5605</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dayton Physicians LLC, Upper valley</name>
      <address>
        <city>Troy</city>
        <state>Ohio</state>
        <zip>45373</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Gross, MD</last_name>
      <phone>937-293-1622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellSpan Health Ephrata Cancer Center</name>
      <address>
        <city>Ephrata</city>
        <state>Pennsylvania</state>
        <zip>17522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Tabatabai, MD</last_name>
      <phone>717-721-4838</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellSpan Health Adams Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Tabatabai, MD</last_name>
      <phone>717-339-2638</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellSpan Health Sechler Family Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>Pennsylvania</state>
        <zip>17042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Tabatabai, MD</last_name>
      <phone>717-270-2238</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kaplan, MD</last_name>
      <phone>412-578-4492</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>WellSpan Health York Cancer Center</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amir Tabatabai, MD</last_name>
      <phone>717-741-8303</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Augusta Health Cancer Center</name>
      <address>
        <city>Fishersville</city>
        <state>Virginia</state>
        <zip>22939</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kyler, MD</last_name>
      <phone>540-245-7047</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours Cancer Institute Medical Oncology at Memorial Regional</name>
      <address>
        <city>Mechanicsville</city>
        <state>Virginia</state>
        <zip>23116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Irvin, MD</last_name>
      <phone>804-594-3131</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours Cancer Institute Medical Oncology at St. Francis</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Irvin, MD</last_name>
      <phone>804-893-8717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bon Secours Cancer Institute Medical Oncology at St. Mary's</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Irvin, MD</last_name>
      <phone>804-893-8717</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Ltd./HSHS St. Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HSHS St. Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Ltd./HSHS St. Mary's Hospital Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>HSHS St. Mary's Hospital Medical Center</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Ltd./HSHS St. Clare Memorial Hospital</name>
      <address>
        <city>Oconto Falls</city>
        <state>Wisconsin</state>
        <zip>54154</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Green Bay Oncology, Ltd./Door County Memorial Hospital</name>
      <address>
        <city>Sturgeon Bay</city>
        <state>Wisconsin</state>
        <zip>54135</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Jaslowski, MD</last_name>
      <phone>920-884-3135</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202439s001lbl.pdf</url>
    <description>FDA Package Insert for Rivaroxaban (Xarelto)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202155s000lbl.pdf</url>
    <description>FDA Package Insert for Apixaban (Eliquis)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206316lbl.pdf</url>
    <description>FDA Package Insert for Edoxaban (Savaysa)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022512s007lbl.pdf</url>
    <description>FDA Package Insert for Dabigatran (Pradaxa)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020287s050lbl.pdf</url>
    <description>FDA Package Insert for Dalteparin (Fragmin)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020164s083lbl.pdf</url>
    <description>FDA Package Insert for Enoxaparin (Lovenox)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021345s023lbl.pdf</url>
    <description>FDA Package Insert for Fondaparinux (Arixtra)</description>
  </link>
  <link>
    <url>http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/009218s107lbl.pdf</url>
    <description>FDA Package Insert for Warfarin (Coumadin)</description>
  </link>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>April 11, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rivaroxaban (Xarelto)</keyword>
  <keyword>Apixaban (Eliquis)</keyword>
  <keyword>Edoxaban (Savaysa)</keyword>
  <keyword>Dabigatran (Pradaxa)</keyword>
  <keyword>Warfarin (Coumadin)</keyword>
  <keyword>Low molecular weight heparin (LMWH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual-level de-identified datasets will be made available to investigators working under an institution with a Federal Wide Assurance (FWA) who formally submit a request to Alliance Foundation Trials LLC (AFT). Prior to the release of datasets, AFT ensures certain requirements, e.g., IRB approval and data use agreement, are in place. These datasets will be available within 6 months of publication of the manuscript and following a formal request by an investigator to and approval from AFT.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>AFT-28</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.allianceforclinicaltrialsinoncology.org/main/public/standard.xhtml?path=%2FPublic%2FAFT</doc_url>
      <doc_comment>Email the study team at CANVAS@AllianceFoundationTrials.org.</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
